The MiPS assay tests for the presence of two prostate cancer biomarkers in post-DRE urine specimens: PCA3 gene mRNAs, found to be overactive in 95% of all PCa-s, and TMPRSS2: ERG mRNAs, which is also a strong indicator of PCa. This evidence concerns the gene ERG and posterior cortical atrophy.